MedTrace Logo

A Real World Study to Evaluate Effectiveness of Avastin (Bevacizumab) for First Line Treatment of Patients With Metastatic Colorectal Cancer and Known KRAS Status

NCT02831842 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4278

Last updated 2018-01-26

No results posted yet for this study

Summary

This non-interventional study will meta-analyze overall survival outcomes among the participants with metastatic colorectal cancer (mCRC) with available V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) status, who received firstline treatment with bevacizumab containing treatment regimen in routine clinical practice. The study leveraging secondary data from existing cohorts in the United Stats of America (USA), Germany, Australia, and Denmark.

Conditions

Interventions

DRUG

Anti-EGFR-Containing Regimen

Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.

DRUG

Bevacizumab-containing regimen

Study protocol does not specify any particular bevacizumab containing regimen. The data will be collected retrospectively.

DRUG

Chemotherapy

Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.

Sponsors & Collaborators

Principal Investigators

  • Germany: PEI Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-09
Primary Completion
2016-06-09
Completion
2017-11-30

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02831842 on ClinicalTrials.gov